Chromium-insulin reduces insulin clearance and enhances insulin signaling by suppressing hepatic insulin-degrading enzyme and proteasome protein expression in KKAy mice

Frontiers in Endocrinology

Volumn 5, Issue JUL, 2014, Pages

  Wang, Zhong Q ^a   Yu, Yongmei ^a   Zhang, Xian H ^a   Komorowski, James ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b JDS Therapeutics LLC   (United States)

Author keywords

Chromium insulin; Ide; Insulin signaling; Irs 1; Liver; Proteasome

Indexed keywords

CHROMIUM; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INSULINASE; PROTEASOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HORMONE DETERMINATION; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN TOLERANCE TEST; MALE; MOUSE; NONHUMAN; PHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84905443639     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00099     Document Type: Article

References (29)

1. Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr (1998) 17:548-55. doi:10.1080/07315724.1998.10718802
2. Abraham AS, Brooks BA, Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism (1992) 41:768-71. doi:10.1016/0026-0495(92)90318-5
3. A scientific review: the role of chromium in insulin resistance. Diabetes Educ (2004) (Suppl):2-14.
4. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest (2000) 106:453-8. doi:10.1172/JCI10762
5. Anderson RA, Polansky MM, Bryden NA, Canary JJ. Supplemental-chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low-chromium diets. Am J Clin Nutr (1991) 54:909-16.
6. Chen WY, Chen CJ, Liu CH, Mao FC. Chromium supplementation enhances insulin signalling in skeletal muscle of obese KK/HlJ diabetic mice. Diabetes Obes Metab (2009) 11:293-303. doi:10.1111/j.1463-1326.2008.00936.x
7. Wang ZQ, Zhang XH, Russell JC, Hulver M, Cefalu WT. Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr (2006) 136:415-20.
8. Jain SK, Kahlon G, Morehead L, Dhawan R, Lieblong B, Stapleton T, et al. Effect of chromium dinicocysteinate supplementation on circulating levels of insulin, TNF-alpha, oxidative stress, and insulin resistance in type 2 diabetic subjects: randomized, double-blind, placebo-controlled study. Mol Nutr Food Res (2012) 56:1333-41. doi:10.1002/mnfr.201100719
9. Broadhurst CL, Domenico P. Clinical studies on chromium picolinate supplementation in diabetes mellitus - a review. Diabetes Technol Ther (2006) 8:677-87. doi:10.1089/dia.2006.8.677
10. Brandimarti P, Costa-Junior JM, Ferreira SM, Protzek AO, Santos GJ, Carneiro EM, et al. Cafeteria diet inhibits insulin clearance by reduced insulin-degrading enzyme expression and mRNA splicing. J Endocrinol (2013) 219:173-82. doi:10.1530/JOE-13-0177
11. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev (1998) 19:608-24. doi:10.1210/er.19.5.608
12. Hersh LB. The insulysin (insulin degrading enzyme) enigma. Cell Mol Life Sci (2006) 63:2432-4. doi:10.1007/s00018-006-6238-9
13. Tundo GR, Sbardella D, Ciaccio C, Bianculli A, Orlandi A, Desimio MG, et al. Insulin-degrading enzyme (IDE): a novel heat shock-like protein. J Biol Chem (2013) 288:2281-9. doi:10.1074/jbc.M112.393108
14. Haque R, Nazir A. Insulin-degrading enzyme: a link between Alzheimer's and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets (2014) 13(2):259-64.
15. Goldfine ID, Williams JA, Bailey AC, Wong KY, Iwamoto Y, Yokono K, et al. Degradation of insulin by isolated mouse pancreatic acini. Evidence for cell surface protease activity. Diabetes (1984) 33:64-72. doi:10.2337/diab.33.1.64
16. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci (2000) 20:1657-65.
17. Peng Z, Qiao W, Wang Z, Dai Q, He J, Guo C, et al. Chromium improves protein deposition through regulating the mRNA levels of IGF-1, IGF-1R, and Ub in rat skeletal muscle cells. Biol Trace Elem Res (2010) 137:226-34. doi:10.1007/s12011-009-8579-3
18. Sun XJ, Goldberg JL, Qiao LY, Mitchell JJ. Insulin-induced insulin receptor substrate-1 degradation is mediated by the proteasome degradation pathway. Diabetes (1999) 48:1359-64. doi:10.2337/diabetes.48.7.1359
19. Lee NA, Reasner CA. Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. Diabetes Care (1994) 17:1449-52. doi:10.2337/diacare.17.12.1449
20. Kupfer SR, Wilson EM, French FS. Androgen and glucocorticoid receptors interact with insulin degrading enzyme. J Biol Chem (1994) 269:20622-8.
21. Li Q, Ali MA, Cohen JI. Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. Cell (2006) 127:305-16. doi:10.1016/j.cell.2006.08.046
22. Duckworth WC, Bennett RG, Hamel FG. Insulin acts intracellularly on proteasomes through insulin-degrading enzyme. Biochem Biophys Res Commun (1998) 244:390-4. doi:10.1006/bbrc.1998.8276
23. Bennett RG, Fawcett J, Kruer MC, Duckworth WC, Hamel FG. Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme. J Endocrinol (2003) 177:399-405. doi:10.1677/joe.0.1770399
24. Grasso G, Pietropaolo A, Spoto G, Pappalardo G, Tundo GR, Ciaccio C, et al. Copper(I) and copper(II) inhibit Abeta peptides proteolysis by insulin-degrading enzyme differently: implications for metallostasis alteration in Alzheimer's disease. Chemistry (2011) 17:2752-62. doi:10.1002/chem.201002809
25. Grasso G, Salomone F, Tundo GR, Pappalardo G, Ciaccio C, Spoto G, et al. Metal ions affect insulin-degrading enzyme activity. J Inorg Biochem (2012) 117:351-8. doi:10.1016/j.jinorgbio.2012.06.010
26. Smith DM, Chang SC, Park S, Finley D, Cheng Y, Goldberg AL. Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry. Mol Cell (2007) 27:731-44. doi:10.1016/j.molcel.2007.06.033
27. Peters JM, Franke WW, Kleinschmidt JA. Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. J Biol Chem (1994) 269:7709-18.
28. Kunjappu MJ, Hochstrasser M. Assembly of the 20S proteasome. Biochim Biophys Acta (2014) 1843:2-12. doi:10.1016/j.bbamcr.2013.03.008
29. Scheufele F, Wolf B, Kruse M, Hartmann T, Lempart J, Muehlich S, et al. Evidence for a regulatory role of cullin-RING E3 ubiquitin ligase 7 in insulin signaling. Cell Signal (2014) 26:233-9. doi:10.1016/j.cellsig.2013.11.005